AMGEN

Nov 16, 09
	NEW STORY
18:06 ET	Amgen to Present at Lazard Capital Healthcare Conference
Nov 12, 09
09:01 ET	Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
Nov 05, 09
08:03 ET	Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Nov 04, 09
12:22 ET	Call for Applications: The Amgen Award for Science Teaching Excellence
Oct 30, 09
20:44 ET	Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
Oct 21, 09
16:08 ET	Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49
Oct 19, 09
08:00 ET	Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)
Oct 16, 09
13:07 ET	Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting
Oct 15, 09
16:42 ET	Amgen Announces Webcast of 2009 Third Quarter Financial Results
Sep 24, 09
03:37 ET	Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Sep 22, 09
06:28 ET	Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
03:01 ET	Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
Sep 21, 09
05:16 ET	Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Sep 17, 09
18:16 ET	Amgen to Present at the UBS Global Life Sciences Conference
Sep 16, 09
09:00 ET	Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
Sep 15, 09
16:53 ET	Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product
Sep 14, 09
16:34 ET	Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
Sep 13, 09
14:47 ET	Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis
Sep 11, 09
16:32 ET	Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Sep 10, 09
14:16 ET	Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Sep 09, 09
15:23 ET	Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope
Sep 08, 09
17:02 ET	Amgen to Present at the Thomas Weisel Healthcare Conference
Sep 04, 09
16:31 ET	Amgen to Present at the Baird Healthcare Conference
Sep 02, 09
12:00 ET	Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis
Aug 25, 09
16:12 ET	Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
Aug 17, 09
17:07 ET	Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
Aug 13, 09
18:37 ET	Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
07:52 ET	Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs
Aug 11, 09
10:05 ET	Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
Aug 06, 09
16:03 ET	Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Aug 04, 09
16:59 ET	Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
Aug 03, 09
17:03 ET	Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
Jul 27, 09
16:08 ET	Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
16:01 ET	Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
Jul 23, 09
13:27 ET	Amgen Announces Webcast of 2009 Second Quarter Financial Results
Jul 20, 09
12:36 ET	Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium
Jul 17, 09
19:10 ET	Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)
Jul 09, 09
18:42 ET	Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors
Jul 07, 09
17:29 ET	Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
Jul 06, 09
14:29 ET	Winners of the Addressing Psoriasis(TM) Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn
Jun 22, 09
15:29 ET	Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
Jun 17, 09
12:33 ET	34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence
Jun 08, 09
17:34 ET	Amgen to Present at the Goldman Sachs Global Healthcare Conference
Jun 07, 09
03:43 ET	New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP
May 27, 09
09:00 ET	New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance
May 26, 09
07:48 ET	Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
May 15, 09
09:29 ET	Amgen Highlights Data to Be Presented at ASCO
May 13, 09
16:46 ET	Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
May 06, 09
17:38 ET	Amgen Announces Voting Results Of Annual Meeting Of Stockholders
Apr 30, 09
09:30 ET	Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
Apr 23, 09
16:08 ET	Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
Apr 20, 09
16:41 ET	Amgen Announces Webcast of 2009 First Quarter Financial Results
Apr 16, 09
09:34 ET	Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR
Mar 30, 09
17:38 ET	Amgen to Present at the Citigroup Biotech Day
Mar 16, 09
17:20 ET	Amgen to Present at the Cowen and Company Annual Healthcare Conference
Mar 09, 09
20:11 ET	Amgen to Present at the Barclays Capital Global Healthcare Conference
Mar 04, 09
08:10 ET	Photos: 'Project Runway's' Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldn't Let Psoriasis Impact Personal Style
Feb 18, 09
09:30 ET	FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
Feb 11, 09
18:30 ET	Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
Jan 26, 09
16:02 ET	Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
Jan 22, 09
12:42 ET	Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
Jan 20, 09
17:17 ET	Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
Jan 07, 09
16:00 ET	Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
Dec 19, 08
16:06 ET	Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
Dec 16, 08
08:00 ET	Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting
Dec 08, 08
14:00 ET	Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients
Nov 21, 08
08:55 ET	Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
Nov 19, 08
18:57 ET	Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
Nov 10, 08
09:00 ET	Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
Nov 07, 08
13:39 ET	Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Nov 03, 08
16:31 ET	Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
13:17 ET	Call for Applications: The Amgen Award for Science Teaching Excellence
Oct 27, 08
08:00 ET	Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
Oct 22, 08
16:05 ET	Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
Oct 20, 08
15:31 ET	Amgen Announces Webcast of 2008 Third Quarter Financial Results
Mar 23, 04
13:10 ET	Amgen's First Research and Development Day Highlighted 24 of the Approximately 40 Programs in its Pipeline
Mar 10, 04
20:45 ET	Frank Herringer Nominated for Amgen Board of Directors
Mar 09, 04
20:28 ET	Leonard Schaeffer Joins Amgen's Board of Directors
Mar 08, 04
19:14 ET	FDA Approves Innovative, First-In-Class Treatment for a Serious Complication of Chronic Kidney Disease
Feb 25, 04
16:03 ET	Amgen Opens State-of-the-Art Biotechnology Research Campus
Feb 23, 04
08:04 ET	Amgen Announces Webcast of R&D Day With the Investment Community
Feb 07, 04
07:30 ET	New Phase 3 ENBREL Data Show Psoriasis Patients Achieved a Therapeutic Response From 'Step Down' Dosing Regimen
Jan 22, 04
16:00 ET	Amgen's Fourth Quarter 2003 Adjusted Earnings Per Share Increased 31 Percent to 46 Cents; Full Year 2003 Adjusted Earnings Per Share Increased 37 Percent to $1.90
Jan 14, 04
17:01 ET	Amgen Announces Webcast of Fourth Quarter and Full Year 2003 Financial Results
Jan 13, 04
17:45 ET	Amgen Names David J. Scott Senior Vice President, General Counsel and Secretary
Dec 29, 03
11:55 ET	Amgen Named One of Fortune Magazine's '100 Best Companies to Work For'
Dec 15, 03
16:00 ET	Amgen Forecasts Strong 2004 Financial Performance
Dec 09, 03
12:17 ET	Amgen Names David Beier Senior Vice President, Global Government Affairs
11:00 ET	Phase 3 Data Show Palifermin Improves Patient Reported Outcomes in Cancer Patients and Helps Reduce Hospitalizations and Healthcare Resources
Dec 07, 03
12:15 ET	Analysis of Head-to-Head Studies Shows That Aranesp(R) Dosed Every Two Weeks Offers Similar Results With Less Frequent Administration Compared to Epoetin Alfa
Dec 06, 03
12:45 ET	New Data Suggest Aranesp(R) Benefits Patients Suffering From Anemia of Cancer, Who Are Not Receiving Chemotherapy
Dec 01, 03
20:48 ET	Amgen Announces Webcast of Conference Call to Provide Financial Guidance for 2004
Nov 16, 03
17:00 ET	Aranesp(R) Administered Once Monthly Maintains Hemoglobin Levels in Patients With Chronic Kidney Disease
Nov 15, 03
08:00 ET	Cinacalcet HCl Phase 3 Results Demonstrate Improvement in the Management of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease
Nov 11, 03
14:57 ET	Amgen Announces Plans for Epratuzumab
Oct 24, 03
17:30 ET	Long-Term Data Support Sustained Efficacy, Tolerability and Increased Vitality For Psoriatic Arthritis Patients Treated With ENBREL and Landmark Phase 3 Data Show Ankylosing Spondylitis Patients Experienced Partial Clinical Remission, Improved Pain Relief
17:30 ET	New Data Show Many Rheumatoid Arthritis Patients Treated With ENBREL Plus Methotrexate Have Experienced Clinical Remission and Most Had No Progression of Joint Damage
Oct 23, 03
14:15 ET	Science Recognizes Amgen as a Top Employer in Annual Survey
Oct 21, 03
16:01 ET	Amgen's Third Quarter 2003 Adjusted Earnings Per Share Increases 56% to 53 Cents
Oct 20, 03
16:30 ET	FDA Approves ENBREL for Once-Weekly Dosing
Oct 16, 03
09:02 ET	Amgen Names H. Christian Fibiger, Ph.D., and Paul G. Pearson, Ph.D., As Vice Presidents to Lead Research Efforts
Oct 14, 03
16:04 ET	Abgenix and Amgen Clarify Responsibilities for ABX-EGF
Oct 06, 03
20:04 ET	Amgen Announces Webcast of Third Quarter 2003 Financial Results